Camber Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Camber Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-450,000	Closed	-$98.8M	–	46
2021 Q4	$98.8M	Buy	+450,000	New	+$87.5M	3.4%	10
2017 Q3	–	Sell	-350,000	Closed	-$45.1M	–	30
2017 Q2	$45.1M	Sell	350,000 -300,000	-46%	-$36.1M	2.2%	15
2017 Q1	$71.1M	Sell	650,000 -100,000	-13%	-$8.8M	2.88%	10
2016 Q4	$55.3M	Buy	+750,000	New	+$61M	2.88%	16
2014 Q4	–	Sell	-400,000	Closed	-$44.9M	–	46
2014 Q3	$44.9M	Buy	+400,000	New	+$38.1M	4.22%	11

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Camber Capital Management's VRTX Position: Q1 2022 in Review

Camber Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 450,000 shares — an estimated $98.8M sold.

Camber Capital Management first reported a position in VRTX in Q3 2014 and held it in 5 quarters. The position peaked at $98.8M in Q4 2021. 1,073 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Camber Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Camber Capital Management sold 450,000 Vertex Pharmaceuticals shares in Q1 2022, an estimated $98.8M.
Camber Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 5 quarters.
Camber Capital Management's Vertex Pharmaceuticals position peaked at $98.8M in Q4 2021.
1,073 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Camber Capital Management's 13F filing for Q1 2022, filed 16 May 2022.